ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 34,006,567 shares, a decrease of 3.7% from the February 15th total of 35,317,685 shares. Approximately 29.4% of the company’s shares are short sold. Based on an average daily trading volume, of 1,310,304 shares, the short-interest ratio is currently 26.0 days.
A number of hedge funds have recently modified their holdings of ZIOP. Parametric Portfolio Associates LLC boosted its stake in shares of ZIOPHARM Oncology by 6.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 85,837 shares of the biotechnology company’s stock worth $534,000 after acquiring an additional 4,826 shares during the last quarter. State Street Corp raised its position in shares of ZIOPHARM Oncology by 12.8% during the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after purchasing an additional 517,057 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of ZIOPHARM Oncology by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 104,447 shares of the biotechnology company’s stock valued at $649,000 after purchasing an additional 7,946 shares during the period. Adell Harriman & Carpenter Inc. bought a new stake in shares of ZIOPHARM Oncology during the 3rd quarter valued at $141,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ZIOPHARM Oncology by 933.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,918 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 32,444 shares during the period. Institutional investors own 39.74% of the company’s stock.
ZIOP has been the subject of several recent analyst reports. BidaskClub downgraded shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. Zacks Investment Research reissued a “hold” rating on shares of ZIOPHARM Oncology in a research note on Saturday, January 13th. HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the stock a “buy” rating in a research note on Thursday, December 14th. ValuEngine downgraded shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.50.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.34 on Monday. ZIOPHARM Oncology has a fifty-two week low of $3.33 and a fifty-two week high of $7.88. The company has a market cap of $616.12, a P/E ratio of -8.04 and a beta of 1.42.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.59 million. During the same quarter in the previous year, the company earned ($0.11) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. analysts expect that ZIOPHARM Oncology will post -0.58 earnings per share for the current fiscal year.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.